✦ LIBER ✦

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

✍ Scribed by Athanasios G Pallis; Sophia Agelaki; Athina Agelidou; Ioannis Varthalitis; Kostas Syrigos; Nikolaos Kentepozidis; Georgia Pavlakou; Athanasios Kotsakis; Emmanouel Kontopodis; Vassilis Georgoulias

Book ID: 115010280
Publisher: BioMed Central
Year: 2010
Tongue: English
Weight: 359 KB
Volume: 10
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-10-633

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel versus docetaxel plus gemcitab

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

✍ Georgoulias, Vassilis; Androulakis, Nikolaos; Kotsakis, Athanasios; Hatzidaki, D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Docetaxel Versus Docetaxel/Cisplatin in

Docetaxel Versus Docetaxel/Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Analysis of a Multicenter, Randomized Phase III Study

✍ V. Georgoulias; A.G. Pallis; C. Kourousis; A. Alexopoulos; A. Ardavanis; A. Agel 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 150 KB

Open, Randomized, Phase II Study of Sing

Open, Randomized, Phase II Study of Single-Agent Gemcitabine and Docetaxel as First- and Second-Line Treatment in Patients with Advanced Non–Small-Cell Lung Cancer

✍ Christian Manegold; Gabriele Koschel; Dagmar Hruska; Kathrin Schott-von-Römer; J 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 155 KB

Second-line therapy with gefitinib in co

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

✍ G. Robinet; F. Barlesi; P. Fournel; H. Berard; R. Corre; A. Vergnenegre; L. Falc 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 160 KB

P-449 Docetaxel in combination carboplat

P-449 Docetaxel in combination carboplatin as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer

✍ Barata, F.; Camacho, E.; Sousa, A.; Costa, M.S.; Resende, R.; Meleiro, A.; Nogue 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Vandetanib plus docetaxel versus docetax

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

✍ Roy S Herbst; Yan Sun; Wilfried EE Eberhardt; Paul Germonpré; Nagahiro Saijo; Ca 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 327 KB